DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) was founded to develop and commercialize proven cancer therapies in new orphan drug indications, and the Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, according to the Company’s website (see here: www.DelMarPharma.com). SNNLive spoke with Jeffrey A. Bacha, President & CEO/Co-Founder of DelMar Pharmaceuticals, Inc. at the 4th Annual SeeThruEquity MicroCap Investor Conference 2015 in New York City, NY.
Mr. Bacha begins with a brief overview of DelMar Pharmaceuticals, Inc. He continues with a description of the Company’s lead drug in development, VAL-083, background and size of the Glioblastoma market.
On February 26th, 2015, we published an SNN Q&A with DelMar Pharmaceuticals, which you can read here (see here: SNN Q&A with DelMar Pharmaceuticals), and since that interview, Mr. Bacha provided an update on what’s happening at DelMar.
Mr. Bacha concludes with his insights for 2015-2016. Since speaking with Mr. Bacha, the Company has made the following announcements:
For more information about DelMar Pharmaceuticals, Inc., go to: www.DelMarPharma.com
© 2017 Stock News Now
Supported by Superior Web Solutions